<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-SX4R53JJ</identifier><date>2015</date><creator>Jezeršek Novaković, Barbara</creator><relation>documents/doc/S/URN_NBN_SI_doc-SX4R53JJ_001.pdf</relation><relation>documents/doc/S/URN_NBN_SI_doc-SX4R53JJ_001.txt</relation><format format_type="issue">4</format><format format_type="volume">49</format><format format_type="type">article</format><format format_type="extent">str. 315-319, I</format><identifier identifier_type="ISSN">1318-2099</identifier><identifier identifier_type="COBISSID">2078075</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-SX4R53JJ</identifier><language>eng</language><publisher>Association of Radiology and Oncology</publisher><source>Radiology and oncology (Ljubljana)</source><rights>BY</rights><subject language_type_id="eng">Hodgkin lymphoma</subject><subject language_type_id="slv">Hodgkinov limfom</subject><subject language_type_id="eng">immunotoxin</subject><subject language_type_id="slv">imunotoksini</subject><subject language_type_id="slv">kemoterapija</subject><subject language_type_id="eng">new treatment option</subject><subject language_type_id="slv">toksičnost</subject><subject language_type_id="eng">toxicity</subject><title>Immunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphoma</title></Record>